Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT‐787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial

Documenti analoghi

• Genotype–Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers
  di: Jumar Etkins, et al.
  Pubblicazione: (2025)
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1820 (Tarperprumig) in Healthy Adults: Results of a Phase I Study
  di: Avner Sandhu, et al.
  Pubblicazione: (2025)
• Correction to “Genotype‐Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers”
  Pubblicazione: (2026)
• First‐in‐Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin‐S Inhibitor, in Healthy Adult Subjects
  di: Tomoki Kojima, et al.
  Pubblicazione: (2026)
• Ecopipam, a Dopamine D1 Receptor Antagonist: Pharmacokinetics, Mass Balance, and Metabolism in Healthy Volunteers
  di: Virginia D. Schmith, et al.
  Pubblicazione: (2026)